Sanara MedTech (SMTI) director receives 4,385-share restricted stock grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Myers Keith G reported acquisition or exercise transactions in this Form 4 filing.
Sanara MedTech Inc. director Keith G. Myers reported receiving a grant of 4,385 shares of common stock as restricted stock under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The award was made at no cash cost per share and increases his directly held position to 9,325 shares.
The restricted stock will vest on the earlier of the company’s 2027 annual shareholder meeting or June 4, 2027, provided Myers continues to provide certain services to the company through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Myers Keith G
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,385 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 9,325 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Restricted stock grant: 4,385 shares
Grant price: $0.0000 per share
Holdings after transaction: 9,325 shares
+1 more
4 metrics
Restricted stock grant
4,385 shares
Common stock awarded on June 4, 2026
Grant price
$0.0000 per share
Equity compensation, no cash paid
Holdings after transaction
9,325 shares
Total common stock directly held after grant
Vesting outside date
June 4, 2027
Latest vesting date if service condition met
Key Terms
restricted stock, 2024 Omnibus Long-Term Incentive Plan, vest, annual shareholder meeting
4 terms
restricted stock financial
"Represents shares of restricted stock granted by Sanara MedTech Inc."
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
2024 Omnibus Long-Term Incentive Plan financial
"pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan."
vest financial
"The restricted stock will vest on the earlier of (i) the date of the 2027 annual shareholder meeting or (ii) June 04, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What did Sanara MedTech (SMTI) director Keith G. Myers report in this Form 4?
Keith G. Myers reported receiving 4,385 shares of Sanara MedTech common stock as a restricted stock grant. This award was issued under the company’s 2024 Omnibus Long-Term Incentive Plan and reflects compensation, not an open-market stock purchase.
Did Keith G. Myers pay cash for the Sanara MedTech (SMTI) restricted stock grant?
No cash was paid for this restricted stock grant; the transaction price per share is reported as 0.0000. The award represents equity-based compensation granted under Sanara MedTech’s 2024 Omnibus Long-Term Incentive Plan rather than an open-market purchase.
Under which plan was the new Sanara MedTech (SMTI) restricted stock granted?
The restricted stock granted to Keith G. Myers was issued under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. This plan authorizes equity-based awards such as restricted stock to directors and other service providers as part of their compensation.